Intersect ENT Company Profile (NASDAQ:XENT)

Analyst Ratings

Consensus Ratings for Intersect ENT (NASDAQ:XENT) (?)
Ratings Breakdown: 1 Hold Rating(s), 8 Buy Rating(s)
Consensus Rating:Buy (Score: 2.89)
Consensus Price Target: $26.50 (69.98% upside)

Analysts' Ratings History for Intersect ENT (NASDAQ:XENT)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Canaccord GenuityReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016WedbushReiterated RatingOutperform$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016BTIG ResearchInitiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Northland SecuritiesInitiated CoverageOutperform$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2016Cantor FitzgeraldReiterated RatingBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/18/2015Bank of America Corp.Initiated CoverageBuy$26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2015Piper Jaffray Cos.Reiterated RatingBuy$30.00 -> $23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/2/2015Sterne Agee CRTReiterated RatingBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/4/2015JPMorgan Chase & Co.Boost Price TargetOverweight$28.00 -> $37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2015CRT CapitalInitiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/11/2014William BlairInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/25/2014 forward)

Earnings

Earnings History for Intersect ENT (NASDAQ:XENT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q116($0.29)($0.29)$16.92 million$16.69 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q415($0.25)($0.20)$18.36 million$18.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2015Q315($0.29)($0.35)$14.80 million$14.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.26)($0.23)$14.74 million$15.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($0.33)($0.23)$13.00 million$13.37 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.29)($0.16)$12.20 million$13.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q314($0.35)($0.32)$8.20 million$9.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intersect ENT (NASDAQ:XENT)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.31)($0.14)($0.27)
Q2 20165($0.29)($0.12)($0.24)
Q3 20165($0.32)($0.16)($0.24)
Q4 20167($0.22)($0.10)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Intersect ENT (NASDAQ:XENT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intersect ENT (NASDAQ:XENT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/18/2016James StambaughVPSell5,000$15.33$76,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2016James StambaughVPSell500$14.38$7,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016Kieran GallahueDirectorBuy8,000$12.64$101,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2016Amy WolbeckVPSell2,000$20.01$40,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/20/2016Richard E KaufmanCOOSell3,603$18.86$67,952.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Lisa D EarnhardtCEOSell28,500$18.69$532,665.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/21/2016Richard E KaufmanCOOSell3,603$16.51$59,485.53View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Lisa D EarnhardtCEOSell9,000$18.01$162,090.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2016Frederic H MollDirectorSell1,299$18.53$24,070.47View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/8/2016Frederic H MollDirectorSell601$18.56$11,154.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Richard E KaufmanCOOSell3,603$18.65$67,195.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2016Richard E. KaufmanCOOSell7,206$17.93$129,203.58View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Lisa D. EarnhardtCEOSell12,500$19.26$240,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Lisa D EarnhardtCEOSell6,820$19.85$135,377.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015Lisa D EarnhardtCEOSell6,818$18.00$122,724.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Lisa D EarnhardtCEOSell6,818$18.72$127,632.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015Lisa D EarnhardtCEOSell6,818$25.99$177,199.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Frederic H MollDirectorSell10,000$25.21$252,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015Lisa D EarnhardtCEOSell6,818$28.51$194,381.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015James StambaughVPSell12,000$30.52$366,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/15/2015Lisa D EarnhardtCEOSell19,318$29.62$572,199.16View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Lisa D EarnhardtCEOSell19,318$29.30$566,017.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015James StambaughVPSell2,785$23.87$66,477.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Amy WolbeckVPSell16,000$26.25$420,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015James StambaughVPSell8,343$25.50$212,746.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Lisa D EarnhardtInsiderSell19,318$23.56$455,132.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Amy WolbeckVPSell8,000$23.06$184,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015James StambaughVPSell8,343$23.02$192,055.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/17/2015Lisa D EarnhardtInsiderSell19,318$22.69$438,325.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/12/2015Amy WolbeckVPSell8,000$22.12$176,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015James StambaughVPSell8,343$20.98$175,036.14View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Robert H Binney JrVPSell6,300$21.18$133,434.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Cynthia L LuccheseDirectorBuy5,000$17.11$85,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Intersect ENT (NASDAQ:XENT)
DateHeadline
07/22/16 10:17 AMBroker Outlook For Intersect ENT, Inc. (XENT) - Fiscal Standard
07/21/16 07:43 PMEarnings Focus and Crowd Sourced Sentiment Review for Intersect ENT, Inc. (NASDAQ:XENT) - TGP
07/21/16 10:11 AMIntersect ENT, Inc. (NASDAQ:XENT) Expected To Post Sales Of $151.35 - Investor Newswire
07/20/16 08:29 PMTrading Performance and Target Watch for Intersect ENT, Inc. (NASDAQ:XENT) - Press Telegraph
07/20/16 08:29 PMInvestor Watch: Volatility Recap on Shares of: Intersect ENT, Inc. (NASDAQ:XENT) - Engelwood Daily
07/20/16 08:29 PMIntersect ENT, Inc. (NASDAQ:XENT): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/20/16 08:29 PMIs Intersect ENT Inc. (NASDAQ: XENT) Trying To Pull A Fast One On Investors? - Scibility Media
07/20/16 08:32 AMIntersect ENT Announces Preliminary Q2 Figures, Stock Up -
07/19/16 07:33 PMIntersect ENT (Nasdaq: $XENT) Announces Preliminary Q2 Revenue and Business Update
07/19/16 03:05 PMIntersect ENT Schedules Second Quarter 2016 Earnings Release and Conference Call for August 2, 2016 - [Business Wire] - Intersect ENT, Inc. , a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it plans to release second quarter financial results after market close on August 2, 2016.
07/19/16 12:25 PMETF’s with exposure to Intersect ENT, Inc. : July 19, 2016 -
07/18/16 03:41 PMINTERSECT ENT, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Princip -
07/15/16 07:25 AMIntersect ENT, Inc. breached its 50 day moving average in a Bullish Manner : XENT-US : July 15, 2016 -
07/12/16 09:49 AMIntersect ENT Announces Publication of PROGRESS Study of Steroid Releasing Implant in Patients With Frontal Sinus Disease
06/23/16 08:09 PMNotable Tuesday Option Activity: GTLS, XENT, FEYE
06/07/16 03:10 PMINTERSECT ENT, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/02/16 03:05 PMIntersect ENT to Present at William Blair & Company 36th Annual Growth Stock Conference - [Business Wire] - Intersect ENT, Inc. today announced that management will present an overview of the company’s business at the 36th Annual William Blair Growth Stock Conference.
06/01/16 07:00 AMIntersect ENT Announces Completion of Enrollment in RESOLVE II Clinical Trial of New In-Office Implant for Recurrent Chronic Sinusitis - [Business Wire] - Intersect ENT, Inc. , a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced:
03/10/16 12:20 PMIntersect ENT, Inc. – Value Analysis (NASDAQ:XENT) : March 10, 2016 -
03/09/16 07:11 AMIntersect ENT, Inc. breached its 50 day moving average in a Bearish Manner : XENT-US : March 9, 2016 -
02/26/16 03:56 PMINTERSECT ENT, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhib -
02/26/16 09:35 AMBaron Funds Comments on Intersect ENT Inc. - Intersect ENT, Inc. (NASDAQ:XENT) sells a drug coated device (Propel) that is implanted in patients that have had surgery for chronic sinusitis. Shares declined in the quarter after Intersect ENT substantially lowered guidance for revenue growth.
02/25/16 03:36 PMINTERSECT ENT, INC. Files SEC form 10-K, Annual Report -
02/25/16 10:15 AMIntersect ENT, Inc. Earnings Analysis: 2015 By the Numbers -
02/23/16 04:35 PMIntersect ENT reports 4Q loss -
02/23/16 03:05 PMIntersect ENT Reports Fourth Quarter and Year 2015 Results - [Business Wire] - Intersect ENT Inc. , a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the fourth quarter and year ended December 31, 2015.
02/23/16 06:07 AMQ4 2015 Intersect ENT Inc Earnings Release - After Market Close -
02/16/16 01:29 PMAnalysts Say Buy These Stocks: Hologic, Inc. (NASDAQ:HOLX), Intersect ENT, Inc. (NASDAQ:XENT), Zogenix, Inc ... - RiversideGazette.com - Analysts Say Buy These Stocks: Hologic, Inc. (NASDAQ:HOLX), Intersect ENT, Inc. (NASDAQ:XENT), Zogenix, Inc ...RiversideGazette.comWall Street analysts are maintaining Buy rating on Hologic, Inc. (NASDAQ:HOLX) company shares. The one year target on the name currently stands at $42.31. The stock recently touched $33.45 and has moved in the range of $32.62 – 33.47 during the ...
02/16/16 01:29 PMWere Analysts Bullish Intersect ENT Inc (NASDAQ:XENT) This Week? - Sonoran Weekly Review - Were Analysts Bullish Intersect ENT Inc (NASDAQ:XENT) This Week?Sonoran Weekly ReviewOut of 7 analysts covering Intersect ENT (NASDAQ:XENT), 9 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intersect ENT was the topic in 5 analyst reports since August 17, 2015 according to StockzIntelligence Inc. Below is a list ...and more »
02/12/16 03:05 PMIntersect ENT to Report Fourth Quarter and Year 2015 Financial Results - [Business Wire] - Intersect ENT, Inc. , a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its fourth quarter and year 2015 on February 23, 2016.
02/12/16 01:19 PMFederated Investors Inc Increased Intersect Ent Inc (NASDAQ:XENT) by $14.01 Million as Shares Rose - WallStreet.org - Federated Investors Inc Increased Intersect Ent Inc (NASDAQ:XENT) by $14.01 Million as Shares RoseWallStreet.orgFederated Investors Inc increased its stake in Intersect Ent Inc (NASDAQ:XENT) by 74.75% based on its latest Q4 2015 regulatory filing with the SEC. Federated Investors Inc bought 636,988 shares as the company's stock rose 9.28% with the market.
02/10/16 01:11 PMAfter Today's Huge Increase, Is Intersect ENT Inc's Near-Term Analysis Positive? - Sonoran Weekly Review - After Today's Huge Increase, Is Intersect ENT Inc's Near-Term Analysis Positive?Sonoran Weekly ReviewThe stock of Intersect ENT Inc (NASDAQ:XENT) is a huge mover today! The stock is up 4.05% or $0.67 after the news, hitting $17.21 per share. About 181,185 shares traded hands. Intersect ENT Inc (NASDAQ:XENT) has declined 42.39% since July 6, 2015 ...
02/03/16 07:02 PMIs Selling Stock Like Intersect ENT Inc After This Bearish Double Bottom Chart Pattern Winning Strategy? - WallStreet.org - Is Selling Stock Like Intersect ENT Inc After This Bearish Double Bottom Chart Pattern Winning Strategy?WallStreet.orgThe chart of Intersect ENT Inc (XENT) shows a double bottom with $17.07 target or 6.00% below today's $18.16 share price. The 7 months chart pattern indicates high risk for the $508.99 million company. It was reported on Feb, 3 by Finviz.com. If the ...
02/02/16 11:54 AMRecent Broker Updates On Intersect ENT, Inc. (XENT) - Risers & Fallers - Recent Broker Updates On Intersect ENT, Inc. (XENT)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Intersect ENT, Inc. (XENT). The latest broker reports which are currently outstanding on Tuesday 2nd February state 6 analysts have a rating of “strong buy”, 2 analysts ...
02/01/16 03:05 PMIntersect ENT to Present at LEERINK Partners Global Healthcare Conference - [Business Wire] - Intersect ENT, Inc. today announced that management will present an overview of the company’s business at the 5th Annual LEERINK Partners Global Healthcare Conference.
02/01/16 11:38 AMCompany Shares of Intersect ENT, Inc. (NASDAQ:XENT) Drops by -4.4% - Market Briefing - Company Shares of Intersect ENT, Inc. (NASDAQ:XENT) Drops by -4.4%Market BriefingIntersect ENT, Inc. (NASDAQ:XENT) has lost 4.4% during the past week and dropped 20.76% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 6.04%. Intersect ENT, Inc. (NASDAQ:XENT) has ...
02/01/16 11:38 AMIntersect ENT Inc. (XENT) – Product Pipeline Analysis, 2015 Update, Market Research, Trends, Demands, Shares ... - Medgadget.com (blog) - Intersect ENT Inc. (XENT) – Product Pipeline Analysis, 2015 Update, Market Research, Trends, Demands, Shares ...Medgadget.com (blog)MrrBiz25 MarketResearchReports.Biz presents this most up-to-date research on “Intersect ENT Inc. (XENT) – Product Pipeline Analysis, 2015 Update”. Intersect ENT Inc. (Intersect), formerly Sinexus, Inc. is a medical equipment company that provides ...
01/29/16 06:51 PMIntersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany - FierceDrugDelivery - Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in GermanyFierceDrugDelivery(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that InEk, the German Institute for the Hospital Remuneration System, has ...and more »
01/29/16 11:45 AMIntersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany - Business Wire (press release) - Intersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in GermanyBusiness Wire (press release)MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that InEk, the German Institute for the Hospital ...and more »
01/29/16 07:03 AM8:03 am Intersect ENT: InEk has assigned NUB Status 1 for mometasone furoate implants for 2016 -
01/29/16 07:00 AMIntersect ENT Announces NUB Status 1 Designation for PROPEL Sinus Implant in Germany - [Business Wire] - Intersect ENT, Inc. , a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that InEk, the German Institute for the Hospital Remuneration System, has assigned NUB Status 1 for mometasone furoate implants for 2016.
01/28/16 11:35 AMIntersect ENT, Inc. (NASDAQ:XENT) Short Interest Update - WallStreet Prudent - Intersect ENT, Inc. (NASDAQ:XENT) Short Interest UpdateWallStreet PrudentIntersect ENT, Inc. (NASDAQ:XENT) stated gains of 70,008 shares or 2.6% in the short interest. The short interest registered from 2,708,384 on December 31,2015 to 2,778,392 on January 15,2016. In terms of floated shares, the shorted positions stood at ...
01/27/16 06:21 PMIntersect ENT, Inc. (NASDAQ:XENT): Quarterly Earnings Update - Investor Newswire - Intersect ENT, Inc. (NASDAQ:XENT): Quarterly Earnings UpdateInvestor NewswireAs per the brokerage research firms surveyed by Zacks Research, Intersect ENT, Inc. (NASDAQ:XENT) is expected to post earnings per share of $-0.19 for last fiscal quarter. The company can announce the results on or around 2016-02-25. Since the data ...and more »
01/22/16 10:50 AMIntersect Ent, Inc. (XENT) Files Form 4 Insider Selling : Lisa D Earnhardt Sells 12500 Shares - WallStreet Prudent - Intersect Ent, Inc. (XENT) Files Form 4 Insider Selling : Lisa D Earnhardt Sells 12500 SharesWallStreet PrudentIntersect Ent, Inc. (XENT): Lisa D Earnhardt , President and CEO of Intersect Ent, Inc. sold 12,500 shares on Jan 15, 2016. The Insider selling transaction was disclosed on Jan 20, 2016 to the Securities and Exchange Commission in a Form-4 filing.and more »
01/20/16 04:06 PMINTERSECT ENT, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
01/20/16 10:53 AMIntersect ENT, Inc. (NASDAQ:XENT) - Stock Sentiment And ABR Update - Investor Newswire - Intersect ENT, Inc. (NASDAQ:XENT) - Stock Sentiment And ABR UpdateInvestor NewswireZacks Research has given an average broker rating of 1 to Intersect ENT, Inc. (NASDAQ:XENT)'s shares. Zacks assigns a simplified score in between one and five against the complex analysts' ratings. A score towards 1-2 typically means a consensus Buy, ...and more »
01/18/16 10:18 AMIntersect ENT on a Bumpy Ride Post Q4 Preliminary Results - Shares of Intersect ENT Inc. (XENT - Snapshot Report) have had a crazy run since the company announced its preliminary fourth-quarter 2015 results on Jan 11. The stock rallied 7.4% immediately after the announcement (Jan 12), closing 3.6% lower on Jan 13.
12/08/15 12:17 PMINTERSECT ENT, INC. Financials -
11/17/15 07:00 AMIntersect ENT Recognized for Gender Diversity by Watermark and UC Davis - [Business Wire] - Intersect ENT, Inc. , a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced the company’s inclusion in the inaugural Watermark Index, a collaboration between Watermark, a leading Bay Area executive women’s organization, and the University of California, Davis, honoring Bay Area companies that support the advancement of women and promote ...
11/12/15 04:36 PMINTERSECT ENT, INC. Files SEC form 10-Q, Quarterly Report -

Social

About Intersect ENT

Intersect ENT logoIntersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XENT
  • CUSIP:
Key Metrics:
  • Previous Close: $15.59
  • 50 Day Moving Average: $13.87
  • 200 Day Moving Average: $16.52
  • P/E Ratio: N/A
  • P/E Growth: 0.11
  • Market Cap: $441.60M
  • Beta: 0.8
  • Current Year EPS Consensus Estimate: $-1 EPS
  • Next Year EPS Consensus Estimate: $-0.64 EPS
Additional Links:
Intersect ENT (NASDAQ:XENT) Chart for Monday, July, 25, 2016